作为血液学领域顶级学术会议之一,2024年欧洲血液学协会(EHA)年会于2024年6月13日至16日在西班牙马德里召开。以下是入选研究:
1. Preliminary Safety and Efficacy Data from Patients with Relapsed or Refractory B-Cell Malignancies Treated with ICP-248, a Novel BCL2 Inhibitor (Abstract No.: 4207)
2. A Phase II, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Tafasitamab Combined with Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (Abstract No.: 5124) 3. Subcutaneous ICP-B02 (CM355), a Novel Bispecific CD20/CD3 Antibody Showed Promising Efficacy and Favorable Safety Profile in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (Abstract No.: P2097)
4. Orelabrutinib-Lenalidomide-Rituximab in Patients with Untreated Mantle Cell Lymphoma (MCL): Updated Results of the Multicenter, Phase II Polaris Study (Abstract No.: P1141) 5. Orient Study: Orelabrutinib Addition to R-Chop-Like Regimen Adapted to Response in Treatment-Naïve Non-GCB DLBCL (Abstract No.: P1167) 6. The Primary Results of R-MTO Regimen (Rituximab, Methotrexate, Thiotepa, and Orelabrutinib) as the First-Line Induction Therapy in Newly Diagnosed Primary Central Nervous System Lymphoma (Abstract No.: P1193) 7. Orelabrutinib in Combination with PD-1 Inhibitor Inrefractory or Relapsed Primary CNS Lymphoma (Abstract No.: P1194) 8. Real-World Outcomes of Orelabrutinib as First-Line Treatment in CLL/SLL: A Multicenter Study (Abstract No.: P1855) 9. Orelabrutinib in Patients with Indolent Non-Hodgkin Lymphoma (INHL) Intolerant to Prior Bruton Tyrosine Kinase Inhibitors (BTKI): Preliminary Results from a Phase 2 Study (Abstract No.: P2074) 10. Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (CWCLL-001 Study) (Abstract No.: P680) 11. Real-World Analysis of Orelabrutinib in Patients (PTS) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (Abstract No.: PB2562) 12. Phase II Study of Orelabrutinib, Rituximab and Thiotepa (ORT) Combined with or without High-Dose MTX Therapy in Patients with Primary CNS Lymphoma (Abstract No.: PB2964) 13. Different Subtype of DLBCL Patients Treated with R-Chop (Like) Plus Orelabrutinib Regimen: A Real-World Study (Abstract No.: PB3034) 奥布替尼联合R-CHOP-like方案治疗不同亚型DLBCL的真实世界研究(摘要代码:PB3034) 14. Orelabrutinib, Rituximab and High-Dose Methotrexate (HD-MTX) in Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL): A Retrospective Analysis on Efficacy and Safety (Abstract No.: PB3036) 诺诚健华(上交所代码:688428;香港联交所代码:09969)是一家商业化阶段的生物医药高科技公司,专注于恶性肿瘤及自身免疫性疾病领域的一类新药研制。公司现有多个新药产品处于商业化、临床及临床前研发阶段。公司在北京、南京、上海、广州、香港以及美国设有分支机构。 作为血液学领域顶级学术会议之一,2024年欧洲血液学协会(EHA)年会于2024年6月13日至16日在西班牙马德里召开。以下是入选研究:
1. Preliminary Safety and Efficacy Data from Patients with Relapsed or Refractory B-Cell Malignancies Treated with ICP-248, a Novel BCL2 Inhibitor (Abstract No.: 4207)
2. A Phase II, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Tafasitamab Combined with Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (Abstract No.: 5124) 3. Subcutaneous ICP-B02 (CM355), a Novel Bispecific CD20/CD3 Antibody Showed Promising Efficacy and Favorable Safety Profile in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (Abstract No.: P2097)
4. Orelabrutinib-Lenalidomide-Rituximab in Patients with Untreated Mantle Cell Lymphoma (MCL): Updated Results of the Multicenter, Phase II Polaris Study (Abstract No.: P1141) 5. Orient Study: Orelabrutinib Addition to R-Chop-Like Regimen Adapted to Response in Treatment-Naïve Non-GCB DLBCL (Abstract No.: P1167) 6. The Primary Results of R-MTO Regimen (Rituximab, Methotrexate, Thiotepa, and Orelabrutinib) as the First-Line Induction Therapy in Newly Diagnosed Primary Central Nervous System Lymphoma (Abstract No.: P1193) 7. Orelabrutinib in Combination with PD-1 Inhibitor Inrefractory or Relapsed Primary CNS Lymphoma (Abstract No.: P1194) 8. Real-World Outcomes of Orelabrutinib as First-Line Treatment in CLL/SLL: A Multicenter Study (Abstract No.: P1855) 9. Orelabrutinib in Patients with Indolent Non-Hodgkin Lymphoma (INHL) Intolerant to Prior Bruton Tyrosine Kinase Inhibitors (BTKI): Preliminary Results from a Phase 2 Study (Abstract No.: P2074) 10. Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (CWCLL-001 Study) (Abstract No.: P680) 11. Real-World Analysis of Orelabrutinib in Patients (PTS) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (Abstract No.: PB2562) 12. Phase II Study of Orelabrutinib, Rituximab and Thiotepa (ORT) Combined with or without High-Dose MTX Therapy in Patients with Primary CNS Lymphoma (Abstract No.: PB2964) 13. Different Subtype of DLBCL Patients Treated with R-Chop (Like) Plus Orelabrutinib Regimen: A Real-World Study (Abstract No.: PB3034) 奥布替尼联合R-CHOP-like方案治疗不同亚型DLBCL的真实世界研究(摘要代码:PB3034) 14. Orelabrutinib, Rituximab and High-Dose Methotrexate (HD-MTX) in Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL): A Retrospective Analysis on Efficacy and Safety (Abstract No.: PB3036) 诺诚健华(上交所代码:688428;香港联交所代码:09969)是一家商业化阶段的生物医药高科技公司,专注于恶性肿瘤及自身免疫性疾病领域的一类新药研制。公司现有多个新药产品处于商业化、临床及临床前研发阶段。公司在北京、南京、上海、广州、香港以及美国设有分支机构。 生物医药高科技公司诺诚健华(上交所代码:688428 )年会,涉及公司多款不同机制重要靶点的创新药,包括BTK 作为血液学领域顶级学术会议之一,2024年欧洲血液学协会(EHA)年会于2024年6月13日至16日在西班牙马德里召开。以下是入选研究:
作为血液学领域顶级学术会议之一,2024年欧洲血液学协会(EHA)年会于2024年6月13日至16日在西班牙马德里召开。以下是入选研究:
1. Preliminary Safety and Efficacy Data from Patients with Relapsed or Refractory B-Cell Malignancies Treated with ICP-248, a Novel BCL2 Inhibitor (Abstract No.: 4207)
2. A Phase II, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Tafasitamab Combined with Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (Abstract No.: 5124) 3. Subcutaneous ICP-B02 (CM355), a Novel Bispecific CD20/CD3 Antibody Showed Promising Efficacy and Favorable Safety Profile in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (Abstract No.: P2097)
4. Orelabrutinib-Lenalidomide-Rituximab in Patients with Untreated Mantle Cell Lymphoma (MCL): Updated Results of the Multicenter, Phase II Polaris Study (Abstract No.: P1141) 5. Orient Study: Orelabrutinib Addition to R-Chop-Like Regimen Adapted to Response in Treatment-Naïve Non-GCB DLBCL (Abstract No.: P1167) 6. The Primary Results of R-MTO Regimen (Rituximab, Methotrexate, Thiotepa, and Orelabrutinib) as the First-Line Induction Therapy in Newly Diagnosed Primary Central Nervous System Lymphoma (Abstract No.: P1193) 7. Orelabrutinib in Combination with PD-1 Inhibitor Inrefractory or Relapsed Primary CNS Lymphoma (Abstract No.: P1194) 8. Real-World Outcomes of Orelabrutinib as First-Line Treatment in CLL/SLL: A Multicenter Study (Abstract No.: P1855) 9. Orelabrutinib in Patients with Indolent Non-Hodgkin Lymphoma (INHL) Intolerant to Prior Bruton Tyrosine Kinase Inhibitors (BTKI): Preliminary Results from a Phase 2 Study (Abstract No.: P2074) 10. Orelabrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (OFCG) for First-Line Treatment of Chronic Lymphocytic Leukemia: A Multicenter, Investigator-Initiated Study (CWCLL-001 Study) (Abstract No.: P680) 11. Real-World Analysis of Orelabrutinib in Patients (PTS) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (Abstract No.: PB2562) 12. Phase II Study of Orelabrutinib, Rituximab and Thiotepa (ORT) Combined with or without High-Dose MTX Therapy in Patients with Primary CNS Lymphoma (Abstract No.: PB2964) 13. Different Subtype of DLBCL Patients Treated with R-Chop (Like) Plus Orelabrutinib Regimen: A Real-World Study (Abstract No.: PB3034) 奥布替尼联合R-CHOP-like方案治疗不同亚型DLBCL的真实世界研究(摘要代码:PB3034) 14. Orelabrutinib, Rituximab and High-Dose Methotrexate (HD-MTX) in Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL): A Retrospective Analysis on Efficacy and Safety (Abstract No.: PB3036) 诺诚健华(上交所代码:688428;香港联交所代码:09969)是一家商业化阶段的生物医药高科技公司,专注于恶性肿瘤及自身免疫性疾病领域的一类新药研制。公司现有多个新药产品处于商业化、临床及临床前研发阶段。公司在北京、南京、上海、广州、香港以及美国设有分支机构。 )是一家商业化阶段的生物医药高科技公司,专注于恶性肿瘤及自身免疫性疾病领域的一类新药研制。公司现有多个新药产品处于商业化、临床及临床前研发阶段。公司在北京、南京、上海、广州、香港以及美国设有分支机构。